AU2019324405B2 - Phenoxy carboxylic acid compounds and medical uses thereof - Google Patents

Phenoxy carboxylic acid compounds and medical uses thereof Download PDF

Info

Publication number
AU2019324405B2
AU2019324405B2 AU2019324405A AU2019324405A AU2019324405B2 AU 2019324405 B2 AU2019324405 B2 AU 2019324405B2 AU 2019324405 A AU2019324405 A AU 2019324405A AU 2019324405 A AU2019324405 A AU 2019324405A AU 2019324405 B2 AU2019324405 B2 AU 2019324405B2
Authority
AU
Australia
Prior art keywords
compound
bjmu
bromo
dimethylphenoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019324405A
Other languages
English (en)
Other versions
AU2019324405A1 (en
Inventor
Ning JIAO
Yameng LIU
Song Song
Simin Yang
Siwang YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Rising Biotechnology Co Ltd
Original Assignee
Qingdao Rising Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Rising Biotechnology Co Ltd filed Critical Qingdao Rising Biotechnology Co Ltd
Publication of AU2019324405A1 publication Critical patent/AU2019324405A1/en
Assigned to QINGDAO WHOLESOMETECH CO., LTD. reassignment QINGDAO WHOLESOMETECH CO., LTD. Request for Assignment Assignors: BEIJING WHOLESOMEYIRD SCI & TECH CO., LTD.
Application granted granted Critical
Publication of AU2019324405B2 publication Critical patent/AU2019324405B2/en
Assigned to QINGDAO RISING BIOTECHNOLOGY CO., LTD. reassignment QINGDAO RISING BIOTECHNOLOGY CO., LTD. Request for Assignment Assignors: QINGDAO WHOLESOMETECH CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019324405A 2018-08-23 2019-08-23 Phenoxy carboxylic acid compounds and medical uses thereof Active AU2019324405B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810965558.1 2018-08-23
CN201810965558 2018-08-23
PCT/CN2019/102273 WO2020038464A1 (zh) 2018-08-23 2019-08-23 苯氧酸类化合物及其医药用途

Publications (2)

Publication Number Publication Date
AU2019324405A1 AU2019324405A1 (en) 2021-04-22
AU2019324405B2 true AU2019324405B2 (en) 2022-09-22

Family

ID=69591994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019324405A Active AU2019324405B2 (en) 2018-08-23 2019-08-23 Phenoxy carboxylic acid compounds and medical uses thereof

Country Status (6)

Country Link
US (2) US12365643B2 (enExample)
EP (1) EP3842410A4 (enExample)
JP (1) JP7472139B2 (enExample)
CN (1) CN110857268B (enExample)
AU (1) AU2019324405B2 (enExample)
WO (1) WO2020038464A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113072448B (zh) * 2021-03-31 2022-11-11 五邑大学 一种芳基吉非罗齐衍生物高价碘化合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3707566A (en) * 1970-03-30 1972-12-26 Parke Davis & Co Aryloxypentane compounds
US3759986A (en) * 1970-03-30 1973-09-18 Parke Davis & Co Esters of 2,2-dimethyl-5-(aryloxy)-1-pentanols
US3847994A (en) * 1970-03-30 1974-11-12 Parke Davis & Co 2,2-dimethyl-5-(aryloxy)-valeraldehydes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462067A1 (en) * 1990-06-15 1991-12-18 Warner-Lambert Company Gemfibrozil formulations
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3707566A (en) * 1970-03-30 1972-12-26 Parke Davis & Co Aryloxypentane compounds
US3759986A (en) * 1970-03-30 1973-09-18 Parke Davis & Co Esters of 2,2-dimethyl-5-(aryloxy)-1-pentanols
US3847994A (en) * 1970-03-30 1974-11-12 Parke Davis & Co 2,2-dimethyl-5-(aryloxy)-valeraldehydes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number. 1971711-36-0; 14 November 2017; Hexanenitrile, 6-[4-chloro-2-methyl-5-(1-methylethyl)phenoxy]-2,2-dimethyl- *
CAS Registry Number:. 1493932-49-2; 14 November 2017; Pentanenitrile, 5-[4-chloro-2-methyl-5-(1-methylethyl)phenoxy]-2,2-dimethyl- *
CAS Registry Number; 1467186-48-6; Butanenitrile, 4-[4-chloro-2-methyl-5-(1-methylethyl)phenoxy]-2,2-dimethyl- *
CAS Registry Number; 2009713-28-2; 14 November 2017; Propanenitrile, 3-(4-bromo-2,3,5-trimethylphenoxy)-2,2-dimethyl- *
CAS,Registry Number 2142154-52-5, 14 November 2017; Butanenitrile, 4-(3-bromo-2,5-dimethylphenoxy)-2,2-dimethyl *
CREGER, P., "Structure/Activity Relationship of Gemfibrozil (CI-719) and Related Compounds", Proc. roy. Soc. Med., (1976), vol. 12, page 31 *

Also Published As

Publication number Publication date
US12365643B2 (en) 2025-07-22
CN110857268B (zh) 2022-10-04
CN110857268A (zh) 2020-03-03
WO2020038464A1 (zh) 2020-02-27
JP2021535210A (ja) 2021-12-16
EP3842410A1 (en) 2021-06-30
EP3842410A4 (en) 2022-07-06
JP7472139B2 (ja) 2024-04-22
US20220119333A1 (en) 2022-04-21
US20250313522A1 (en) 2025-10-09
AU2019324405A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
CN108602811B (zh) Fxr受体激动剂
WO2020198712A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
DK2799427T3 (en) Therapeutic compounds
JP2007509842A (ja) 心血管障害の処置のためにＡｐｏＡ１の発現を誘導するための、一酸化窒素部分を含む化合物
CA3128416A1 (en) Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof
WO2022105852A1 (zh) 三嗪二酮类衍生物、其制备方法及其在医药上的应用
JP2009242434A (ja) 代謝性障害の処置のための化合物
JP2013523888A (ja) 抗酸化炎症モジュレーターを使用して肥満を処置する方法
US20250313522A1 (en) Phenoxy carboxylic acid compounds and medical uses thereof
CN108409663B (zh) 微管抑制剂及其制备方法和用途
WO2012159107A1 (en) Inhibition of renal fibrosis
KR101497113B1 (ko) Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
WO2015021894A1 (zh) 新型羟肟酸衍生物及其医疗应用
CN102066362A (zh) 二氢吲哚酮衍生物
KR102106365B1 (ko) 게라닐 게라닐 아세톤 유사체 및 이의 용도
Zuo et al. Design, synthesis and biological evaluation of novel arylpropionic esters for the treatment of acute kidney injury
CN105147677A (zh) 一组2-取代甲酰胺基-3-烷氧基吡啶类衍生物及其制药用途
AU2017341020A2 (en) Urea derivative
CN101054372B (zh) 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
CN115991702B (zh) 芳基c-葡萄糖苷衍生物、其制备方法及其用途
JP7644471B2 (ja) オートファジー阻害剤
CN110251498A (zh) 一类调节法尼醇受体活性的化合物及其用途
CN119591583B (zh) 一种沙坦类化合物及其制备方法和应用
WO2006043510A1 (ja) エステル誘導体及びその医薬用途
CN104892457A (zh) 一种异羟肟酸类衍生物、其药物组合物、制备方法及用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PHENOXY CARBOXYLIC ACID COMPOUNDS AND MEDICAL USES THEREOF

PC1 Assignment before grant (sect. 113)

Owner name: QINGDAO WHOLESOMETECH CO., LTD.

Free format text: FORMER APPLICANT(S): BEIJING WHOLESOMEYIRD SCI & TECH CO., LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: QINGDAO RISING BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER(S): QINGDAO WHOLESOMETECH CO., LTD.